Gramicidin
/ /, Neosporin (gramicidin) is an unknown pharmaceutical. Gramicidin was first approved as Neo-polycin on 1982-01-01. It is used to treat bacterial eye infections and gram-positive bacterial infections in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| eye diseases | D005128 |
Trade Name
FDA
EMA
Combinations
Neomycin polymyxin b sulfates gramicidin, Neosporin (discontinued: Neo-polycin, Neomycin polymyxin b sulfates gramicidin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| johnson and johnson all purpose first aid kit | OTC monograph final | 2023-01-10 |
| johnson and johnson first aid all purpose | OTC monograph final | 2023-01-31 |
| johnson and johnson first aid travel ready | OTC monograph final | 2023-01-31 |
| neo-polycin | ANDA | 2012-09-26 |
| neomycin and polymyxin b sulfates and gramicidin | ANDA | 2024-09-18 |
| neosporin | 2006-10-03 | |
| neosporin kids plus pain relief | OTC monograph final | 2023-01-11 |
| neosporin lip health | C200263 | 2024-11-01 |
| neosporin original | C200263 | 2023-11-23 |
| neosporin pain itch scar | OTC monograph final | 2023-01-11 |
Show 4 more
Indications
FDA
EMA
Show 7 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
68 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Necrosis | D009336 | — | — | 4 | — | — | 3 | 7 | 14 |
| Dental pulp necrosis | D003790 | — | K04.1 | 3 | — | — | 3 | 4 | 10 |
| Dental pulp diseases | D003788 | EFO_0009540 | K04 | 1 | — | 1 | 1 | 3 | 6 |
| Periodontitis | D010518 | EFO_0000649 | K05.3 | 1 | — | — | 1 | 3 | 5 |
| Periapical periodontitis | D010485 | EFO_1001391 | K04.5 | 1 | — | — | 1 | 3 | 5 |
| Infections | D007239 | EFO_0000544 | — | 1 | — | 1 | 1 | 1 | 4 |
| Periapical abscess | D010482 | EFO_1001202 | — | — | 1 | 1 | 1 | 1 | 3 |
| Postoperative pain | D010149 | — | G89.18 | 1 | — | — | 1 | 1 | 3 |
| Communicable diseases | D003141 | — | — | — | — | 1 | 1 | 1 | 3 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial conjunctivitis | D003234 | EFO_1000829 | H10.0 | — | — | 1 | — | — | 1 |
| Conjunctivitis | D003231 | HP_0000509 | H10 | — | — | 1 | — | — | 1 |
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | — | 1 | — | — | 1 |
| Vesico-ureteral reflux | D014718 | EFO_0007536 | N13.7 | — | — | 1 | — | — | 1 |
| Corneal ulcer | D003320 | — | H16.0 | — | — | 1 | — | — | 1 |
| Contracture | D003286 | HP_0001371 | M62.4 | — | — | 1 | — | — | 1 |
| Implant capsular contracture | D057910 | — | — | — | — | 1 | — | — | 1 |
| Hordeolum | D006726 | HP_0010606 | H00.01 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Edema | D004487 | HP_0000969 | R60.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomatognathic diseases | D009057 | — | K08.9 | 1 | — | — | — | 1 | 2 |
| Asymptomatic diseases | D058070 | — | — | 1 | — | — | — | — | 1 |
| Intractable pain | D010148 | — | — | 1 | — | — | — | — | 1 |
| Regeneration | D012038 | — | — | 1 | — | — | — | — | 1 |
| Covid-19 | D000086382 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Periapical diseases | D010483 | EFO_0010688 | — | — | — | — | — | 3 | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 3 | 3 |
| Pancreatic cyst | D010181 | HP_0001737 | K86.2 | — | — | — | — | 2 | 2 |
| Blindness | D001766 | HP_0000618 | H53.12 | — | — | — | — | 2 | 2 |
| Pancreatitis | D010195 | HP_0001733 | K85 | — | — | — | — | 1 | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
| Cysts | D003560 | — | — | — | — | — | — | 1 | 1 |
| Stem cell research | D057905 | — | — | — | — | — | — | 1 | 1 |
| Surgical wound infection | D013530 | — | — | — | — | — | — | 1 | 1 |
| Bites and stings | D001733 | — | — | — | — | — | — | 1 | 1 |
Show 39 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Gramicidin |
| INN | gramicidin s |
| Description | Gramicidin, also called gramicidin D, is a mix of ionophoric antibiotics, gramicidin A, B and C, which make up about 80%, 5%, and 15% of the mix, respectively. Each has 2 isoforms, so the mix has 6 different types of gramicidin molecules. They can be extracted from Brevibacillus brevis soil bacteria. Gramicidins are linear peptides with 15 amino acids. This is in contrast to unrelated gramicidin S, which is a cyclic peptide.
|
| Classification | Unknown |
| Drug class | natural antibiotics (undefined group) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1405-97-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201469 |
| ChEBI ID | — |
| PubChem CID | 45267103 |
| DrugBank | DB00027 |
| UNII ID | 5IE62321P4 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Gramicidin
+
Neomycin
+
Polymyxin b
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,490 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,855 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use